Ivan Chavez, MD
Interventional Cardiology · Minneapolis, MNNPI 1417915158
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,669 of the $6,000 with a category attached, or 61.2%. 10 manufacturers reported payments, led by Medtronic at 32.0% of the total. Reporting peaked in 2024 at $2,650 and has fallen 80.1% since, to $528 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.
Across 46 payments — averaging $130.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$1K
- Boston Scientific$933
- Penumbra, Inc.$585
- Abiomed$499
- Cardiovascular Systems Inc.$180
- plus $483 from 4 others
Across 87 payments — averaging $6121.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$496K
- Abbott$29K
- Boston Scientific$8K
What the payments were for
- Travel & lodging$3,66961%
- Food & beverage$2,33139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $1,918 |
| Abbott | 8 | $1,401 |
| Boston Scientific | 4 | $933 |
| Penumbra, Inc. | 5 | $585 |
| Abiomed | 6 | $499 |
| Cardiovascular Systems Inc. | 1 | $180 |
| Gentuity, LLC | 1 | $176 |
| Heartflow, Inc. | 2 | $163 |
| Cathworks, Inc. | 1 | $121 |
| Boehringer Ingelheim | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$963
- LOTUS EDGE$933
- OPTIS$928
- Indigo System$458
- Impella$260
- XIENCE SIERRA$190
- Diamondback Coronary$180
- Gentuity HF-OCT Imaging System$176
- Vis-Rx Prime$176
- COREVALVE EVOLUT R$166
- FFRct$151
- Dragonfly OCT$131
- FFRangio$121
How this compares
$6,000 in reported general payments places this provider in the 50th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 281 | $307,471 |
| JardianceEmpagliflozin | 153 | $147,235 |
| EntrestoSacubitril/Valsartan | 86 | $107,485 |
| Repatha SureclickEvolocumab | 61 | $59,512 |
| XareltoRivaroxaban | 42 | $51,322 |
| FarxigaDapagliflozin Propanediol | 50 | $47,333 |
| Metoprolol Succinate | 330 | $5,759 |
| Atorvastatin Calcium | 210 | $3,565 |
| Rosuvastatin Calcium | 247 | $3,257 |
| Losartan Potassium | 228 | $2,596 |
| Spironolactone | 192 | $1,319 |
| Ezetimibe | 51 | $1,165 |
| Lisinopril | 99 | $1,125 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 81 | $1,095 |
| Furosemide | 169 | $885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $23 | $147,235153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 84 interventional cardiology providers in Minnesota.
Other interventional cardiology in Minneapolis
- Emmanouil BrilakisMinneapolis$548K
- Wesley PedersenMinneapolis$493K
- Michael ManolesMinneapolis$201K
- Jay TraverseMinneapolis$198K
- Robert WilsonMinneapolis$176K
- Yale WangMinneapolis$168K
- Steven RohMinneapolis$67K
- Stefan BertogMinneapolis$64K
- Konstantinos VoudrisMinneapolis$46K
- Michael MooneyMinneapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.